Table 2.
Outcome of DTC in different ATA and TNM stages showing more persistent thyroid cancer in higher stages.
ATA risk group | NED No. (%) |
PD No. (%) |
P value |
---|---|---|---|
Low risk | 77 (80.2) | 19 (19.8) | <0.0001 |
Intermediate risk | 77 (64) | 48 (38.4) | |
High risk | 21 (28.0) | 54 (72.0) | |
TNM stages | |||
I | 68 (68.7) | 31 (31.3) | <0.001 |
II | 97 (64.7) | 53 (35.3) | |
III | 9 (33.3) | 18 (66.7) | |
IV | 1 (5) | 19 (95) | |
Total | 175 (59) | 121 (41) |
NED, no evidence of disease; PD, persistent disease.